Results 111 to 120 of about 27,778 (225)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys). [PDF]

Leuk Res Rep, 2023
Okikiolu J, Woodley C, Cadman-Davies L, O'Sullivan J, Radia D, Garcia NC, Harrington P, Kordasti S, Asirvatham S, Sriskandarajah P, Saunders J, Saha C, Sanchez I, deLavallade H, McLornan DP, Harrison CN.   +15 more
europepmc   +1 more source

Interferon Alfa in the treatment of B-cell chronic lymphocytic leukemia [PDF]

, 1994
Adolf, D., Bergmann, L., Dietzfelbinger, H., Emmerich, B., Knauf, W. U., Langenmayer, Irmgard, Maubach, P. A., Mitrou, P. S., Nerl, C., Thiel, E., Ziegle-Heitbrock, H. W. L.   +10 more
core   +1 more source

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma. [PDF]

Front Oncol, 2021
Jia DD, Niu Y, Zhu H, Wang S, Ma T, Li T.   +5 more
europepmc   +1 more source

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review. [PDF]

Case Rep Ophthalmol Med, 2021
Gimeno-Carrero M, Suárez-Fernández MJ, Alonso-Martín B, de-Pablo-Cabrera A, Garrido-Ruíz MC, Mencía-Gutiérrez E.   +5 more
europepmc   +1 more source

Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA [PDF]

, 2017
Kim, Eric H, Manley, Brandon J, Potretzke, Aaron M, Strope, Seth A, Vetter, Joel M   +4 more
core   +2 more sources

Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)

Современная ревматология
Objective: to evaluate the efficacy and safety of the type I interferon (IFN) receptor inhibitor anifrolumab (AFM, Safnelo®) in patients with systemic lupus erythematosus (SLE) in real-life clinical practice over an observation period of 6 months ...
T. M. Reshetnyak, E. A. Aseeva, A. A. Shumilova, N.  Yu. Nikishina, S. I. Glukhova, S. Yu. Shkireeva, A. M. Lila   +6 more
doaj   +1 more source

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. [PDF]

Cancer Discov, 2022
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A.   +30 more
europepmc   +1 more source

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study. [PDF]

Int J Infect Dis, 2021
Pandit A, Bhalani N, Bhushan BLS, Koradia P, Gargiya S, Bhomia V, Kansagra K.   +6 more
europepmc   +1 more source

Eradicating chronic Hepatitis C Viraemia : lessons learnt during the last decade [PDF]

, 2005
Over the last decade a better understanding of the mechanism for immune disposal of hepatocytes infected with the Hepatitis C virus enabled the design of antiviral regimens with increasing efficacy.
Pullicino, Edgar
core  

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. [PDF]

Qual Life Res, 2023
McLouth LE, Zheng Y, Smith S, Hodi FS, Rao UN, Cohen GI, Amatruda TT, Dakhil SR, Curti BD, Nakhoul I, Chandana SR, Bane CL, Marinier DE, Lee SJ, Sondak VK, Kirkwood JM, Tarhini AA, Wagner LI.   +17 more
europepmc   +1 more source